Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 13/20 | 0.73 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6120543 | 0.94 | EZH2 (0.65) | EZH2HPGDSTSHRL3MBTL1 | |
| SCHEMBL6120386 | 0.85 | EZH2 (0.64) | EZH2ATML3MBTL1GLAMEN1 | |
| SCHEMBL6120964 | 0.85 | EZH2 (1.00) | EZH2TSHRATML3MBTL1GLA | |
| SCHEMBL8738303 | 0.84 | EZH2 (0.73) | EZH2ATML3MBTL1GLAMEN1 | |
| SCHEMBL8738904 | 0.84 | EZH2 (0.55) | EZH2HPGDSATML3MBTL1GLA | |
| Trifluoroacetic Acid SCHEMBL6120919 | 0.81 | EZH2 (0.59) | EZH2HPGDSATML3MBTL1GLA | |
| SCHEMBL6120685 | 0.80 | EZH2 (0.62) | EZH2TSHRL3MBTL1GLAMEN1 | |
| SCHEMBL8738546 | 0.79 | EZH2 (0.80) | EZH2ATML3MBTL1GLAMEN1 | |
| SCHEMBL8738664 | 0.79 | EZH2 (0.65) | EZH2ATML3MBTL1GLAMEN1 | |
| Trifluoroacetic Acid SCHEMBL6120836 | 0.79 | EZH2 (0.86) | EZH2TSHRATML3MBTL1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885HPGDS 1377/4885TSHR 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.